SLC25A32 and neoplasm: This may indicate that SLC25A32, which is highly expressed in cancer, acts as a mitochondrial FAD transporter and responds to the high level of mitochondrial oxidative phosphorylation in cancer cells to provide energy for the rapid proliferation of cancer cells and improve the anti-oxidative stress ability of tumour.